Omega 3 fatty acid for the prevention of dementia (Review)

Lim WS, Gammack JK, Van Niekerk JK, Dangour A

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2006, Issue 1

http://www.thecochranelibrary.com

WILEY
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>2</td>
</tr>
<tr>
<td>Objectives</td>
<td>3</td>
</tr>
<tr>
<td>Methods</td>
<td>4</td>
</tr>
<tr>
<td>Results</td>
<td>8</td>
</tr>
<tr>
<td>Discussion</td>
<td>8</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>8</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>8</td>
</tr>
<tr>
<td>References</td>
<td>9</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>11</td>
</tr>
<tr>
<td>Data and Analyses</td>
<td>14</td>
</tr>
<tr>
<td>What's New</td>
<td>14</td>
</tr>
<tr>
<td>History</td>
<td>14</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>14</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>14</td>
</tr>
<tr>
<td>Index Terms</td>
<td>15</td>
</tr>
</tbody>
</table>
Background

Accruing evidence from observational and epidemiological studies suggests an inverse relationship between dietary intake of omega 3 polyunsaturated fatty acid (PUFA) and risk of dementia. Postulated mechanisms that might qualify omega 3 PUFA as an interventional target for the primary prevention of dementia include its anti-atherogenic, anti-inflammatory, anti-oxidant, anti-amyloid and neuroprotective properties.

Objectives

To review the evidence that omega 3 PUFA supplementation prevents cognitive impairment and dementia in cognitively intact elderly persons.

Search methods

The Cochrane Dementia and Cognitive Improvement Group’s (CDCIG) Specialized register, MEDLINE, EMBASE, CINAHL PsycINFO, AMED AND CENTRAL and several ongoing trials databases were searched on 5 and 6 October 2005. The CDCIG Register is updated regularly and contains records from all major medical databases and many ongoing trials databases.

Selection criteria

In order to be selected, trials needed to be randomized, placebo-controlled, doubled blinded, of minimum study duration of 6 months, involved persons aged 60 years and above without pre-existing dementia at study onset, and employed cognitive endpoints.

Data collection and analysis

Reviewers, working independently, were to select, quality assess and extract relevant data where appropriate and possible. In comparing intervention with placebo, the pooled odds ratios or weighted mean differences and standardized mean difference were to be estimated.

Main results

There were no randomized trials found in the search that met the selection criteria. Results of two clinical trials are expected in 2008.
Authors’ conclusions

There is a growing body of evidence from biological, observational and epidemiological studies that suggests a protective effect of omega 3 PUFA against dementia. However, until data from randomized trials become available for analysis, there is no good evidence to support the use of dietary or supplemental omega 3 PUFA for the prevention of cognitive impairment or dementia.

Plain Language Summary

There is no evidence that dietary or supplemental omega 3 polyunsaturated fatty acid (PUFA) reduces the risk of cognitive impairment or dementia in healthy elderly persons without pre-existing dementia.

Evidence from biological and epidemiological studies suggests that lower omega 3 PUFA intake is associated with an increased risk of dementia. In experimental animal models, dietary enhancement of docosahexanoic acid (a long-chain omega 3 PUFA) slows the expression of Alzheimer’s pathology and improves cognitive performance. These findings raise the possibility of similar preventative benefits in humans. Omega 3 PUFA have also been shown to reduce vascular risk, inflammation and oxidative damage. Available clinical studies comparing the occurrence of Alzheimer’s disease between elderly persons with different levels of dietary omega 3 PUFA consumption, suggest that risk of Alzheimer’s disease is significantly reduced among those with higher levels of fish and omega 3 PUFA consumption. However, because these studies are not randomized trials, they provide insufficient evidence to recommend dietary and supplemental omega 3 PUFA for the explicit purpose of dementia prevention.

This review yielded no clinical trials that could confirm or refute the utility of omega 3 PUFA in preventing cognitive impairment or dementia. This is an important area that is in pressing need of further research.

Background

Congruent with the graying demographic trend in many developed countries, it is projected that there will be an exponential rise in the prevalence of age-associated diseases like dementia. It has been estimated, based on demographic projections, that between 1990 and 2010, the number of cases of Alzheimer’s disease (AD) in developed countries will rise by nearly 40%. Dementia is a progressive debilitating syndrome that imposes a huge burden on individual caregivers, health care professionals, and resource utilization, especially institutionalized care. Current therapeutic approaches do not reverse the progression of the disease, and often only offer short-term symptomatic improvement (Cummings 2004). In the current economic climate of increasing health care costs and tightening health care budgets, there is a pressing need for effective preventative measures of dementia.

Studies suggest that the pathogenesis of dementia involves the complex interactions between genetic and environmental risk factors. In recent years, there has been an increased interest in nutrition as an important modifiable environmental risk factor. Nutrients and metabolites such as folic acid, vitamin B12, vitamin B6 and homocysteine have been the focus of attention (Nourhashemi 2000). This interest has widened to encompass the investigation of an implicating role of low omega 3 polyunsaturated fatty acid (PUFA) status in the etiology of dementia. This is supported by studies suggesting that omega 3 PUFA consumption may be beneficial in the treatment of other neuropsychiatric conditions such as depression (Hibbeln 1998) and bipolar affective disorder (Stoll 1999).

Omega 3 PUFAs have been in the limelight since the astute observation by Bang in the 1970s that the Greenland Inuit had low mortality from coronary artery disease despite a diet that is rich in fat (Bang 1971). It was proposed that this could be because of the high content of omega 3 fatty acid in the Inuit diet, which consisted largely of fish, seal and whale (Dyerberg 1975). The marine sources of omega 3 PUFA (also called n-3 PUFA) include eicosapentanoic acid (EPA or 20:5), docosahexanoic acid (DHA, 22:6) and docosapentanoic acid (DPA, 22:5), which are the longer chain omega 3 forms. Alpha linolenic acid (ALA, 18:3) is the shorter chain omega 3 fatty acid from nuts and vegetable oils. Although an endogenous process exists whereby ALA can be partially converted to the longer chain omega 3 fatty acids, there is some debate about the effectiveness of this conversion, depending on other dietary factors and whether assessed over short or long term. For this reason, the effectiveness of ALA may differ from that of the longer chain forms (Hooper 2004).

Several mechanisms have been postulated for the protective role of
omega 3 PUFA in dementia. Firstly, omega 3 PUFA may protect against dementia by reducing cardiovascular disease (Tully 2003) and non-haemorrhagic stroke risk (He 2002; Iso 2001). Cardiovascular disease has been shown to increase the risk of dementia and its major subtypes, AD and vascular dementia (Hofman 1997). The beneficial effects of long chain PUFA in reducing vascular risk include antiarrhythmic, anti-thrombotic, anti-inflammatory and antiatherogenic effects (Friedland 2003). Omega 3 PUFA may also lower serum triglyceride levels, lower blood pressure and improve endothelial function (Din 2004). Secondly, omega 3 PUFA may reduce dementia risk by reducing the synthesis of pro-inflammatory cytokines, and thereby, attenuate the pro-inflammatory components of the dementia disease process (Akiyama 2000). Thirdly, since DHA is a primary component of membrane phospholipids in the brain, adequate omega 3 PUFA status may protect against dementia by the maintenance of membrane integrity and neuronal function. In animal models, dietary enhancement of DHA was shown to promote neuronal membrane excitability, increase neurotransmitter levels, and reduce neuronal damage (Morris 2003b). In behavioural models, this translated into superior learning acquisition and memory performance over animals fed control diets (Calon 2004; Gamoh 1999). Lastly, omega 3 PUFA may play a pivotal role in the expression of ß-amyloid, a major component of the hallmark plaque pathology in Alzheimer’s disease, by reducing its production from amyloid precursor protein and increasing its clearance (Friedland 2003).

A cross-sectional study reported that higher fatty fish and marine omega 3 PUFA consumption was associated with a reduced risk of impaired cognitive performance in a middle-aged population (Kalmijn 2004). Corroborative evidence of an inverse relationship between fish or omega 3 PUFA intake and risk of dementia can be found in observational (Conquer 2000; Tully 2003; Ruggiero 2004) and epidemiological studies (Barberge-Gateau2002; Huang 2005; Kyle 1999; Morris 2003a; Morris 2003b). The epidemiological studies are large population-based studies with a prospective design and reasonable duration of follow up (3.9 to 10 years). However, several methodological concerns deserve mention. In the Chicago Health and Aging Project, the self-reported food frequency questionnaire was administered just 2 years before clinical diagnosis of dementia (Morris 2003a; Morris 2003b). Thus, bias from subclinical dementia cannot be excluded; the observed association with omega 3 PUFA levels may be a consequence of altered dietary habits rather than a cause of cognitive decline. In the PAQUID (Personnes Agees QUID) study, dietary data was limited to only 4 frequencies of intake without collecting information for specific fat groups, and vitamin E intake was not adjusted for in the analysis (Barberge-Gateau2002). The Cardiovascular Health Cognition Study likewise did not adjust for vitamin E in the analysis; also, adjustment by education and income attenuated the benefits of fatty fish on dementia risk (Huang 2005). Lastly, the results of Kyle et al were preliminary and only presented in a one-page research letter with few methodological details (Kyle 1999).

Moreover, the evidence of an inverse relationship between omega 3 PUFA intake and risk of dementia is not unambiguous. While an inverse association between cognitive decline with age and omega 3 PUFA was reported in a population-based study that examined fatty acid composition of erythrocyte membranes (Heude 2003), this was not replicated in a recent prospective cohort study that utilised dietary questionnaire to assess fatty acid intake (Morris 2005). This study found that dietary intake of fish was associated with slower cognitive decline with age over a 6 year follow-up, although there was no consistent association with omega 3 fatty acids, suggesting the possibility that the protective effect of fatty fish consumption may not be fully accounted for by omega-3 PUFA. The Rotterdam study did not demonstrate any influence of low omega 3 PUFA intake on dementia risk after a mean follow-up of 6 years, thereby not confirming the positive findings of an earlier report on the same study which was based on a shorter follow up of 2 years and a smaller number of incident dementia cases (Kalmijn 1997; Engelhart 2002). Likewise, the Canadian Study of Health and Aging did not find any beneficial effects from omega 3 PUFA (Laurin 2003). In addition, interventional studies of omega 3 fatty acids in dementia are limited, and tend to be small in numbers and of short follow up duration (Terano 1999; Yehuda 1996). Larger scale clinical interventional trials examining the effect of increased omega 3 intake on coronary artery disease tend not to examine dementia risk or cognition endpoints.

Given that most omega-3 PUFA are ingested in the form of oily fish or fish oil capsules, reports of environmental contamination with various toxic compounds such as mercury, dioxin and polychlorinated biphenyls (PCBs) are disconcerting. Adult exposures to dioxins and PCBs may lead to an excess of total cancers, while high mercury levels in some fish species may attenuate their cardioprotective effects (Guallar 2002). A recent Cochrane review did not demonstrate an adverse effect of dietary or supplementation omega-3 PUFA on total mortality, combined cardiovascular events or cancers in people with or at high risk of cardiovascular disease, and in the general population (Hooper 2004). Some reports show that fish oil may worsen glycemic control in diabetes, but two meta-analyses found no adverse effect (Friedberg 1998; Montori 2000).

The cumulative summation of many small protective effects of omega 3 PUFA may add up to a significant protective effect on dementia risk and age-related cognitive decline. Thus, this systematic review aims to pool together the evidence to examine the effect of omega 3 PUFA in the primary prevention of dementia in the non-demented population.

**Objectives**

**Primary**
To determine from available evidence whether dietary or supplemental omega 3 fatty acid is effective in the primary prevention of dementia in non-demented older persons.

Secondary
To review the benefit of treatment with omega 3 fatty acid on cognition measures, and whether its protective effect (if any) is dependent on the dose.

METHO DS

Criteria for considering studies for this review

Types of studies
This review is restricted to all randomized controlled trials (RCTs) in non-demented participants where omega 3 PUFA was compared with placebo, provided that there was a minimum follow up of 6 months (26 weeks or 180 days) and dementia was excluded at baseline. Studies which do not have cognitive endpoints (defined as either incident dementia or measurement on a cognition rating scale or instrument) are excluded. There is no restriction on language, publication type and sample size. Trials are excluded if the allocation of treatment and placebo was not random. If a study meets all the criteria for inclusion but does not present sufficient data allowing an estimate of effect (and this information is not available from the authors), the study is treated as a “dropout” instead of being excluded, and listed in a table of eligible studies to indicate that it has not been overlooked.

Types of participants
Eligible participants include persons aged 60 years and above, without a diagnosis of dementia or cognitive impairment at study onset. The chief consideration for the age cut-off is to ensure a characteristic representation of the neurodegenerative diseases that are typically seen in older persons (such as Alzheimer’s disease), as the heterogeneous subset of young onset dementias are often due to underlying illnesses that are very different in etiology, presentation, and rate of progression from that encountered in the elderly population. Subjects with a diagnosis of delirium and acute confusion at study onset are excluded. There should be a demonstration of adequate screening to exclude pre-existing dementia or cognitive impairment via the use of cognitive instruments, dementia rating scales or psychometric tests that have been reported in peer-reviewed journals. Subjects with known cognitive impairment but not amounting to dementia are excluded from this review. These include (but are not limited to) the following diagnostic categories: dementia prodrome, incipient dementia, cognitive impairment no dementia (CIND), mild cognitive impairment (MCI), vascular cognitive impairment (VCI), age-associated memory impairment (AAMI), and age associated cognitive decline (AACD). While some of these terms were conceptually meant to characterize memory changes reflecting a “normal” stage of aging, more recent data has cast some doubt on this premise (Ritchie 2000). In particular, MCI has been recognized as a diagnostically heterogeneous entity with a significant progression to dementia (Petersen 2001). There is no restriction on the basis of gender, ethnicity, study setting or other characteristics.

Types of interventions
Any type of omega 3 PUFA treatments, as monotherapy or in combination with other pharmacological treatment (including vitamins), if the design allows the effect of omega 3 PUFA to be isolated. There are broadly two types of omega 3 treatment of relevance: i) longer chain omega 3 PUFA: eicosapentanoic acid (EPA), docosahexanoic acid (DHA) or docosapentanoic acid (DPA), either individually or in combination, and/or ii) shorter chain PUFA such as alpha linolenic acid (ALA). The intervention should involve dietary supplementation or a provided diet. There is no restriction on dose or dosing schedule. Studies are excluded if the intervention consisted solely of dietary advice, or if the intervention was based solely on self report without definitive provision of dietary supplements (usually in the form of pills or oils) or a diet. In studies where the intervention consisted of a provided diet, these would still be eligible if treatment was compared with usual diet. Otherwise, trials where treatment was compared with another active treatment and not to a placebo, are excluded. Studies are also excluded if they include multiple risk factor intervention on lifestyle factors other than diet and supplementation (unless the effect of diet or supplementation can be separated out from the other interventions).

Types of outcome measures
Primary outcome
Incident dementia of any cause as defined by accepted international diagnostic criteria, such as those of the International Classification of Diseases (ICD-10: WHO 1992), American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM III-R; DSM-IV), and the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA: McKhann 1984).
Secondary outcomes
Mean change in measures of memory and cognitive function from baseline to follow-up as measured by peer-reviewed mental status tests such as the Mini-Mental State Examination (MMSE), or more detailed psychometric assessment such as the Wechsler Memory Scale.

Proportion reporting progression using peer reviewed global rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

Search methods for identification of studies
The Cochrane Dementia and Cognitive Improvement Group’s Specialised Register was searched on 5 October 2005 using the terms: Omega-3 or Omega 3 or Polyunsaturated fatty acid or PUFA or unsaturated fatty acids or Essential fatty acids or EFA or Eicosapentanoic acid or EPA or Ethyl-Eicosapentanoic acid or E-EPA or Docosahexanoicacid or DHA or Docosapentanoic acid or DPA or Alpha-linolenic acid or ALA or Fish oil or n-3 fatty acids or long chain fatty acids or primrose oil or linseed oil or oily fish or flaxseed oil or fish oil.

CENTRAL (Cochrane Library issue 3, 2005) was searched on 5 October 2005 using the following search strategy:

MEDLINE (1966-2005/10, week 1) was searched on 5 October using the following search strategy:

PsycINFO (1872-2005/09, week 4) was searched on 6 October using the following search strategy:

EMBASE (1980-2005/09) was searched on 6 October using the following search strategy:

CINAHL (1982-2005/08) was searched on 6 October using the following search strategy:

Search terms: Omega-3 or Omega 3 or Polyunsaturated fatty acid or PUFA or unsaturated fatty acids or Essential fatty acids or EFA or Eicosapentanoic acid or EPA or Ethyl-Eicosapentanoic acid or E-EPA or Docosahexanoic acid or DHA or Docosapentanoic acid or DPA or Alpha-linolenic acid or ALA or Fish oil or n-3 fatty acids or long chain fatty acids or primrose oil or linseed oil or oily fish or flaxseed oil or fish oil.

As studies without cognitive endpoints will be excluded, health-related quality of life and mood outcomes will be collected only if present along with cognitive endpoints. Where available, outcomes of explanatory interest such as treatment dose, and blood levels of PUFA status (such as cholesteryl ester-EPA) are collected.

Mean change in measures of validated health-related quality of life such as the SF-36 (Ware 1993).

Behavioural outcomes relating to depression and anxiety using accepted international criteria such as the DSM criteria, or validated rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

Proportions reporting progression using peer reviewed global rating scales such as the Clinical Dementia Rating (CDR).

Proportion reporting progression using peer reviewed global rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

Mean change in measures of validated health-related quality of life such as the SF-36 (Ware 1993).

Behavioural outcomes relating to depression and anxiety using accepted international criteria such as the DSM criteria, or validated rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

As studies without cognitive endpoints will be excluded, health-related quality of life and mood outcomes will be collected only if present along with cognitive endpoints. Where available, outcomes of explanatory interest such as treatment dose, and blood levels of PUFA status (such as cholesteryl ester-EPA) are collected.

Mean change in measures of memory and cognitive function from baseline to follow-up as measured by peer-reviewed mental status tests such as the Mini-Mental State Examination (MMSE), or more detailed psychometric assessment such as the Wechsler Memory Scale.

Proportion reporting progression using peer reviewed global rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

As studies without cognitive endpoints will be excluded, health-related quality of life and mood outcomes will be collected only if present along with cognitive endpoints. Where available, outcomes of explanatory interest such as treatment dose, and blood levels of PUFA status (such as cholesteryl ester-EPA) are collected.

Mean change in measures of memory and cognitive function from baseline to follow-up as measured by peer-reviewed mental status tests such as the Mini-Mental State Examination (MMSE), or more detailed psychometric assessment such as the Wechsler Memory Scale.

Proportion reporting progression using peer reviewed global rating scales such as the Geriatric Depression Scale (Gompertz 1993), Hamilton Depression Inventory and Hamilton Anxiety Rating scale (Hamilton 1960), Hospital Anxiety and Depression Scale (Zigmond 1983), the Beck Depression Inventory and Beck Anxiety Inventory (Beck 1961).

As studies without cognitive endpoints will be excluded, health-related quality of life and mood outcomes will be collected only if present along with cognitive endpoints. Where available, outcomes of explanatory interest such as treatment dose, and blood levels of PUFA status (such as cholesteryl ester-EPA) are collected.
#5 #1 or #2 or #3 or #4
#6 "Preventive-T rials"/ without-subheadings , adverse-effects , #1 or #2 or #3 or #4

where pregnancy, in-adolescence, in-adulthood, in-infancy-and- childhood, in-old-age, in-pregnancy , in-uter o
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and (random* or placebo* or double-blind*)
#12 #11 and cognit*
AMED (1985-2005/09) was searched on 6 October using the following search strategy:
#1 explode "FATTY-ACIDS"
#2 "fatty acid*" or fats or omega-3 or "omega 3" or PUFA or EPA or E-EPA or DHA or DPA or ALA
#3 n-3-fatty-acid* or "n-3 fatty acid*" or "linseed oil" or "flaxseed oil" or "fish oil" or "salmon oil" or "cod liver oil"
#4 "eicosapentanoic acid*" or "docosahexanoic acid*" or "dosapen tanico acid*" or "alpha-linolenic acid*" or "ethyl-eicosapentanoic acid*"
#5 #1 or #2 or #3 or #4
#6 "PREVENTION-" in DE,ET,MT
#7 prevent* or avoid*
#8 #6 or #7
#9 #5 and #8
#10 #9 and (healthy or normal or elderly or older)
#11 #10 and cognit*
ClinicalTrials.gov and NRR (National Research Register - http://www.update-software.com/projects/nrr/) were searched for ongoing trials on 6 October 2005. The search engines Copernic and Google were used with the search terms omega, trial, cognition on 27 September 2006 using the terms: Omega-3 or Omega 3 or Polyunsaturated fatty acid or PUFA or unsaturated fatty acids or Essential fatty acids or EPA or Eicosapentanoic acid or EPA or Ethyl-Eicosapentanoic acid or E-EPA or Docosahexanoic acid or DHA or Docosapentanoic acid or EPA or Alpha-linolenic acid or ALA or Fish oil or n-3 fatty acids or long chain fatty acids or primrose oil or linseed oil or oily fish or flaxseed oil or fish oil. Where appropriate, the search was narrowed using the terms: "prevent*" or "avoid*", "dementia", "randomized controlled trial" or "clinical study".

## Data collection and analysis

When studies are available for analysis, the following methods will be applied:

### Study selection

Based on the title of publication and the abstract identified from the trial search, irrelevant citations will be discarded by the reviewers (WL, AD, JG and JVN). If there is any possibility that the article could be relevant, the full text article will be retrieved for further assessment. Two reviewers (WL, JG or JVN) will independently decide which trials fit the inclusion criteria. Any disagreement will be resolved by discussion between the reviewers, with referral to a third reviewer to adjudicate any persisting differences. Excluded studies and reasons for exclusion will be stated.

### Assessment of methodological quality

Although there are a number of scales devised for assessing the quality of RCTs, there is no evidence that complex and time-consuming scales are more effective than simple scales. The following areas have some evidence of association with biased estimates of treatment effect (Juni 2001), and will be assessed:

- a) randomization (method of generation and concealment of allocation)
- b) blinding (blinding of observers / participants to the treatment allocation)
- c) loss to follow-up (presence of withdrawals and loss to follow up, and the analysis of these).

The quality assessment will include an evaluation of the following components for each included study. Each component will be categorized as Adequate, Unclear, Inadequate, or Not Used, based on the following:

- Randomization (allocation generation) - adequate when the allocation sequence protects against biased allocation to the comparison groups
- Randomization (allocation concealment) - adequate when measures are taken to ensure that decision for recruitment precedes knowledge of allocation
● Blinding - adequate when the outcome assessor is unaware of the allocation
● Loss to follow up - adequate if less than 20% of participants withdrew from the trial, or were lost to follow up
● Intention to treat analysis - adequate when participants were analysed in the groups to which they were originally randomized

On the basis of the above criteria, trials will be given a quality rating of A (adequate), B (unclear), and C (inadequate), based on the quality categories as described in the Cochrane Reviewers’ Handbook 4.2.2. (Alderson 2004). A description of the quality of each study will be given based on a summary of the above components.

Data Extraction
This will be performed by two reviewers (AD, JG or JVN), who will independently enter data onto a data extraction form. The extracted data will be checked for agreement between reviewers, and any discrepancies that persist after discussion will be resolved by a third reviewer (WL). Missing data will be obtained from the authors whenever possible. To avoid introducing bias, this unpublished information will be obtained in writing, on forms designed for this purpose. The data will then be entered into Review Management software (RevMan 4.2).

The following data will be collected:

● Report - author, year and source of publication
● Study - study setting, sample characteristics
● Patients - demographics, screening to exclude pre-existing cognitive impairment or dementia, absence of acute confusion or delirium at study onset, other concomitant medical conditions or medications that may affect cognition
● Research design and features - sampling mechanism, treatment assignment mechanism, blinding, drop-out rates, length of follow-up, pertinent design features (e.g. crossover design)
● Intervention - type, duration, dose, timing, mode of delivery
● Outcome - number of patients randomized, nature of outcome, estimate and standard error, adverse effects, reason for non-adherence, measurement of omega-3 status

For continuous data, the summary statistics required for each outcome are the mean change from baseline, the standard deviation of the mean change, and the number of patients in each treatment group at each assessment. Where changes from baseline are not reported, the mean, the standard deviation and number of patients for each treatment group at each time point will be extracted if available. For binary data, the numbers in each treatment group and the numbers experiencing the outcome of interest will be sought. The baseline assessment is defined as the latest available assessment prior to commencement of intervention.

To allow an intention-to-treat analysis, the data will be sought irrespective of compliance, whether or not the patient was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data are not available in the publications, “on-treatment” data, or the data of those who completed the trial, will be sought and indicated as such.

In studies where a cross-over design was used, only data from the first treatment phase after randomization will be eligible for inclusion.

Data Analysis
For binary outcomes, such as presence or absence of dementia, Petro odds ratio and its 95% confidence interval (CI) will be used to measure treatment effect. The number needed to treat (NNT) will also be calculated. In addition, a weighted estimate of the typical treatment effect across trials will be calculated.

With regards to outcomes measured arising from ordinal rating scales, these will be treated as continuous variables if the ordinal scale appears to be approximately normally distributed or if the analysis suggests parametric tests are appropriate. If the normal approximation is not deemed appropriate, the study will be regarded as a “dropout” rather than ineligible, and will be listed in a table of eligible studies.

For continuous variables, summary statistics (number of participants, mean and standard deviation) will be required for each outcome of each treatment group for change from baseline. For crossover trials only the data from the first treatment period will be used. When change from baseline results are not reported, the required summary statistics will be calculated from the baseline and assessment time treatment group means and standard deviations. In this case a zero correlation between the measurements at baseline and assessment time will be assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta-analysis.

The measure of the treatment difference for any outcome will be the weighted mean difference when the pooled trials use the same rating scale or test. Where different rating scales or tests are used, the trial specific summary effect will be transformed to a standardized (scale-free) mean difference, which is calculated as the absolute mean difference divided by the standard deviation. Overall estimates of the treatment difference will be presented. A fixed-effects model will be used in the first instance but if there is evidence of heterogeneity, then either only homogeneous results will be pooled, or a random-effects model will be used (in which case the confidence intervals would be broader than those of a fixed-effects model).

If numbers permit, subgroup analysis will be performed to examine the impact of dose, composition (e.g. marine versus plant sources), baseline cognitive function (e.g. baseline MMSE) and whether Omega 3 PUFA supplementation was in isolation or an adjunct to other therapy. Reasons for heterogeneity in studies will be explored and, if necessary, sensitivity analyses will examine the effects of excluding study subgroups, e.g. those studies with lower methodological quality. If study numbers permit, a funnel plot will be used to detect publication bias.
RESULTS

Description of studies
See: Characteristics of excluded studies; Characteristics of ongoing studies.

Our search yielded only 2 randomized trials in elderly persons with cognitive endpoints (Terano 1999; Yehuda 1996). Both are treatment trials in patients with established Alzheimer's disease or vascular dementia, and thus, not applicable to our review. There are no randomized trials examining the primary prevention of cognitive decline or dementia.

However, there are two ongoing randomized controlled trials with cognitive endpoints of omega 3 PUFA supplementation in healthy cognitively intact older persons that may be relevant to a future update of the review. The OPAL study (Dangour 2004) is a double-blind randomized placebo-controlled trial examining the effect of daily supplementation with 700 mg omega 3 PUFA (500 mg DHA and 200 mg EPA) for 24 months on cognitive performance in healthy older persons aged 70-79 with good cognitive function (MMSE equals or greater than 24 out of 30 points at baseline) who are recruited from 20 primary care practices. It is scheduled for completion at the end of 2007. Secondly, there is the MEMO study (van de Rest 2005), which is scheduled for completion in end 2007. Elderly persons aged 65 years and above with baseline MMSE greater than 21 will be randomized to one of three groups: 400 mg EPA-DHA, 2 g EPA-DHA or placebo oil in capsules.

Excluded studies
We did not consider a recently concluded study which examined the effects of 3-month EPA/DHA supplementation on depressed mood and cognitive function in adults aged 20-65 as participants were too young to meet inclusion criteria (Rogers 2005). There is another ongoing randomized trial in healthy young adults (Singhal 2004) that is also of an inappropriate age group for the purposes of our review.

Risk of bias in included studies
Not applicable

Effects of interventions
There is no evidence that omega 3 PUFA reduce the risk of cognitive impairment or dementia.

AUTHORS’ CONCLUSIONS

Implications for practice
On the basis of currently available evidence, omega 3 PUFA supplementation cannot be recommended for the explicit purpose of preventing cognitive impairment or dementia.

However, it is not uncommon in clinical practice to encounter well-meaning patients and their families who specifically enquire about dietary recommendations for lowering the risk of dementia. Evidence from large well-conducted population studies suggests that a high intake of saturated or trans-unsaturated fats increases, while fatty fish and marine omega 3 PUFA consumption decreases the risk of cognitive impairment and incident dementia (Barberger-Gateau 2002; Kalmijn 2004; Morris 2003a; Morris 2003b). Thus, in this regard, it is not unreasonable to encourage adequate consumption of fatty fish as part of general dietary recommendations that may also confer benefits of reducing the risk of stroke and heart disease (Friedland 2003).

Implications for research
Although biological and epidemiological studies support the utility of omega 3 PUFA in preventing cognitive impairment or dementia, there is a pressing need for randomized double-blind placebo-controlled trials to confirm or refute this premise. While risk reduction is an important measure, there are other issues in need of investigation. These include:

- The effects of omega 3 PUFA on sub-populations
- The effects of omega 3 PUFA source
- Optimal dose and exposure duration
- Sustenance of effect after cessation of omega 3 PUFA supplementation
- Whether there is a differential benefit on dementia risk for those with APOE-epsilon 4 compared with those without (Huang 2005).
- Whether omega 3 PUFA supplementation can retard or stop the progression of disease diagnosed at an early, mild stage (i.e. secondary prevention treatment trials)
- Whether therapy started in middle life has an advantage over therapy started in the 60s or early 70s.

DISCUSSION
Not applicable

ACKNOWLEDGEMENTS
The reviewers would like to acknowledge Dymphna Hermans, Co-ordinator, Cochrane Dementia and Cognitive Impairment Group,
and Katherine Hicks, Review Co-ordinator, Cochrane Dementia Cognitive Impairment Group, for advice in writing the protocol and assistance in the trial search, as well as Christine Derrick for providing consumer comments.

References

References to studies excluded from this review

Rogers 2005  {published data only}

Singhal 2004  {published data only}
A Singhal. The influence of n-3 fatty acid supplementation on cognitive and vascular function; a randomised, controlled trial. National Research Register 2004k.

References to ongoing studies

Dangour 2004  {published data only}
Smithson WH. The OPAL Study. Old people and n-3 long-chain polysaturated fatty acids. ISRCTN Register 2005.

van de Rest 2005  {published data only}

Additional references

Akiyama 2000

Alderson 2004

Bang 1971

Barberger-Gateau2002

Beck 1961

Calon 2004

Conquer 2000

Cummings 2004

Din 2004

DSM III-R

DSM-IV

Dyerberg 1975
Engelhart 2002

Friedberg 1998

Friedland 2003

Gamoh 1999

Gompertz 1993

Guallar 2002

Hamilton 1960

He 2002

Heude 2003
Heude B, Ducimetiere P, Berr C. Cognitive decline and diet. The Cochrane Database of Systematic Reviews 2003;144.

Hibbeln 1998
Hibbeln JR. Fish consumption and major depression. Lancet 1998;351:1213.

Hofman 1997

Hooper 2004

Huang 2005

Iso 2001

Juni 2001

Kalmijn 1997

Kalmijn 2004

Kyle 1999
Kyle DJ, Schaefer E, Patton G, Beiser A. Low serum docosahexaenoic acids is a significant risk factor for Alzheimer’s disease. Lipids 1999;34:245S.

Laurin 2003

McKhann 1984

Montori 2000

Morris 2003a

Morris 2003b

Morris 2005
Nourhasémi 2000

Petersen 2001

Ritchie 2000

Ruggiero 2004

Stoll 1999

Terano 1999

Tully 2003

Ware 1993

WHO 1992

Yehuda 1996

Zigmond 1983

* Indicates the major publication for the study
Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rogers 2005</td>
<td>This study has been completed; write-up is pending results of blood fatty acid assays. However, via personal communication (October 2005) we know the triallists recruited only younger age adults (20-65 years) with mild to moderate depression</td>
</tr>
<tr>
<td>Singhal 2004</td>
<td>This is an ongoing study scheduled for completion 30 Sep 2006. Recruited only younger age participants</td>
</tr>
</tbody>
</table>

Characteristics of ongoing studies  [ordered by study ID]

Dangour 2004

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Older People And n-3 Long-chain polyunsaturated fatty acids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>Healthy, cognitively normal (baseline MMSE greater than 23) adults aged 70-79 years. Recruited from 20 general practices.</td>
</tr>
<tr>
<td>Interventions</td>
<td>1. 0.7g n-3 oil (0.5g DHA/0.2g EPA) daily for 24 months 2. Placebo</td>
</tr>
<tr>
<td>Starting date</td>
<td>01/03/2004</td>
</tr>
<tr>
<td>Contact information</td>
<td>Dr Alan Dangour  London School of Hygiene and Tropical Medicine  Keppel Street  London  United Kingdom  WC1E 7HT</td>
</tr>
</tbody>
</table>
van de Rest 2005

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>Mental Health in Elderly Maintained with Omega-3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>Older persons aged &gt;65 years with baseline MMSE &gt;21</td>
</tr>
</tbody>
</table>
| Interventions       | 1. 400mg EPA-DHA for 26 weeks  
|                     | 2. 2g EPA-DHA for 26 weeks  
|                     | 3. Placebo                                   |
| Outcomes            | 1. RAVLT Rey Auditory Verbal learning test (primary outcome)  
|                     | 2. Weschler forward and backward digit span  
|                     | 3. Trails A and B                            |
|                     | 4. Stroop test                                |
|                     | 5. Fluency test                               |
|                     | 6. Quality of life (WHOQOL-BREF)              |
| Starting date       | 01/10/2005                                   |
| Contact information | Ondine van de Rest  
|                     | Division of Human Nutrition  
|                     | Wageningen University  
|                     | Postbus 8129                                  |
|                     | Wageningen                                   |
|                     | 6700 EV                                      |
|                     | Netherlands                                   |
| Notes               |                                                |
DATA AND ANALYSES

This review has no analyses.

WHAT'S NEW

Last assessed as up-to-date: 11 November 2005.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 November 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 3, 2005
Review first published: Issue 1, 2006

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 November 2005</td>
<td>New citation required and conclusions have changed</td>
<td>Substantive amendment</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

WL: initiated and drafted the protocol. He will be involved in trial search and selection, adjudication of disagreements in data extraction, data entry, statistical analyses, and writing of the final review.

JG, JVN, AD: provided an equal input into the conceptual development and editing of the protocol, and was involved in data interpretation and review of the final draft.

Both JG and JVN also searched trials, selected trials, and extracted data, while AD was involved in data extraction.

Contact Editor: Peter Whitehouse
Consumer Editor: Christine Derrick

This review has been peer reviewed in November 2005.
DECLARATIONS OF INTEREST

Alan Dangour is the principal investigator of the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study.

INDEX TERMS

Medical Subject Headings (MeSH)

Cognition Disorders [*prevention & control]; Dementia [*prevention & control]; Fatty Acids, Omega-3 [*therapeutic use]; Randomized Controlled Trials as Topic

MeSH check words

Aged; Humans